{"id":52464,"date":"2012-09-12T01:16:25","date_gmt":"2012-09-12T01:16:25","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/stem-cell-researchers-use-gene-therapy-to-restore-immune-systems-in-bubble-boy-disease.php"},"modified":"2012-09-12T01:16:25","modified_gmt":"2012-09-12T01:16:25","slug":"stem-cell-researchers-use-gene-therapy-to-restore-immune-systems-in-bubble-boy-disease","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/gene-therapy\/stem-cell-researchers-use-gene-therapy-to-restore-immune-systems-in-bubble-boy-disease.php","title":{"rendered":"Stem cell researchers use gene therapy to restore immune systems in &#39;Bubble Boy&#39; disease"},"content":{"rendered":"<p><p>    ScienceDaily (Sep. 11, 2012)  UCLA    stem cell researchers have found that a gene therapy regimen    can safely restore immune systems to children with so-called    \"Bubble Boy\" disease, a life threatening condition that if left    untreated can be fatal within one to two years.  <\/p>\n<p>    In the 11-year study, researchers were able to test two therapy    regimens for 10 children with ADA-deficient severe combined    immunodeficiency (SCID). During the study, they refined their    approach to include a light dose of chemotherapy to help remove    many of the blood stem cells in the bone marrow that are not    creating an enzyme called adenosine deaminase (ADA), which is    critical for the production and survival of healthy white blood    cells, said study senior Dr. Donald Kohn, a professor of    pediatrics and of microbiology, immunology, and molecular    genetics in Life Sciences and a member of the Eli and Edythe    Broad Center of Regenerative Medicine and Stem Cell Research at    UCLA.  <\/p>\n<p>    The refined gene therapy and chemotherapy regimen proved    superior to the other method tested in the study, restoring    immune function to three of the six children who received it,    Kohn said. Going forward, an even further refined regimen using    a different type of virus delivery system will be studied in    the next phase of the study, which already has enrolled eight    of the 10 patients needed.  <\/p>\n<p>    The study appears Aug. 30 in the advance online issue of the    peer-reviewed journal Blood.  <\/p>\n<p>    \"We were very happy that in the human trials we were able to    see a benefit in the patients after we modified the protocol,\"    Kohn said. \"Doctors treating ADA-deficient SCID have had too    few options for too long, and we hope this will provide them    with an efficient and effective treatment for this devastating    disease.\"  <\/p>\n<p>    Children born with SCID, an inherited immunodeficiency, are    generally diagnosed at about six months. They are extremely    vulnerable to infectious diseases and don't grow well. Chronic    diarrhea, ear infections, recurrent pneumonia and profuse oral    candidiasis commonly occur in these children. SCID cases occur    in about 1 of 100,000 births  <\/p>\n<p>    Currently, the only treatment for ADA-deficient SCID calls for    injecting the patients twice a week with the necessary enzyme,    Kohn said, a life-long process that is very expensive and often    doesn't return the immune system to optimal levels. These    patients also can undergo bone marrow transplants from matched    siblings, but matches can be very rare.  <\/p>\n<p>    About 15 percent of all SCID patients are ADA-deficient. Kohn    and his team used a virus delivery system that he had developed    in his lab in the 1990s to restore the gene that produces the    missing enzyme necessary for a healthy immune system. To date,    about 40 children with SCID have received gene therapy in    clinical trials around the world, Kohn said.  <\/p>\n<p>    Two slightly different viral vectors were tested in the study,    each modified to deliver healthy ADA genes into the bone marrow    cells of the patients so the needed enzyme could be produced    and make up for the cells that don't have the gene. Four of the    10 patients in the study remained on their enzyme replacement    therapy during the gene therapy study. There were no side    effects, but their immune systems were not sufficiently    restored, Kohn said.  <\/p>\n<p>    In the next six patients, the enzyme therapy was stopped and a    small dose of chemotherapy was given before starting the gene    therapy to deplete the ADA-deficient stem cells in their bone    marrow. Of those patients, half had their immune systems    restored. The human findings confirmed another study, also    published recently in Blood by Kohn and UCLA colleague Dr.    Denise Carbonaro-Sarracino, which tested the techniques in    parallel, using a mouse model of ADA-deficient SCID.  <\/p>\n<\/p>\n<p>Visit link:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.sciencedaily.com\/releases\/2012\/09\/120911111626.htm\" title=\"Stem cell researchers use gene therapy to restore immune systems in &#39;Bubble Boy&#39; disease\">Stem cell researchers use gene therapy to restore immune systems in &#39;Bubble Boy&#39; disease<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> ScienceDaily (Sep. 11, 2012) UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called \"Bubble Boy\" disease, a life threatening condition that if left untreated can be fatal within one to two years <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/gene-therapy\/stem-cell-researchers-use-gene-therapy-to-restore-immune-systems-in-bubble-boy-disease.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[24],"tags":[],"class_list":["post-52464","post","type-post","status-publish","format-standard","hentry","category-gene-therapy"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/52464"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=52464"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/52464\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=52464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=52464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=52464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}